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Abstract
Background: Neo-adjuvant chemotherapy is an integral part of multi-modality approach in the
management of locally advanced breast cancer and it is vital to predict the response in order to
tailor the regime for a patient. The common final pathway in the tumor cell death is believed to be
apoptosis or programmed cell death and chemotherapeutic drugs like other DNA-damaging agents
act on rapidly multiplying cells including both the tumor and the normal cells by following the same
common final pathway. This could account for both the toxic effects and the response. Absence or
decreased apoptosis has been found to be associated with chemo resistance. The change in
expression of apoptotic markers (Bcl-2 and Bax proteins) brought about by various
chemotherapeutic regimens is being used to identify drug resistance in the tumor cells. A
prospective clinical study was conducted to assess whether chemotherapy induced toxic effects
could serve as reliable predictors of apoptosis or response to neo-adjuvant chemotherapy in
patients with locally advanced breast cancer.
Methods: 50 cases of locally advanced breast cancer after complete routine and metastatic work
up were subjected to trucut biopsy and the tissue evaluated immunohistochemically for apoptotic
markers (bcl-2/bax ratio). Three cycles of Neoadjuvant Chemotherapy using FAC regime (5-
fluorouracil, adriamycin, cyclophosphamide) were given at three weekly intervals and patients
assessed for clinical response as well as toxicity after each cycle. Modified radical mastectomy was
performed in all patients three weeks after the last cycle and the specimen were re-evaluated for
any change in the bcl-2/bax ratio. The clinical response, immunohistochemical response and the
drug-induced toxicity were correlated and compared.
Descriptive studies were performed with SPSS version 10 and the significance of response was
assessed using paired t-test. Significance of correlation between various variables was assessed
using chi-square test and coefficient of correlation calculated by Pearson correlation coefficient.
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Results:  There was a statistically significant correlation observed between clinical,
immunohistochemical response (bcl-2/bax ratio) and the drug-induced toxicity.
Conclusion:  Responders also had significant toxicity while non-responders did not show
significant toxicity following neoadjuvant chemotherapy. The chemotherapy-induced toxicity was
observed to be a cost effective and reliable predictor of response to neo-adjuvant chemotherapy.
Background
Neo-adjuvant chemotherapy (NACT) is an integral part of
multi-modality approach in the management of locally
advanced breast cancer (LABC). It is required both for the
local control (to ensure microscopically free margins dur-
ing surgery) and distant or systemic control [1-5]. In the
past few years, considerable research has been done on the
molecular aspects of breast cancer. The recognition that
tumor growth rate is a product of the proliferative activity
and the rate of cell death has lead to a reappraisal of tradi-
tional views of tumor response and resistance to cytotoxic
Drugs [2].
Apoptosis is a closely regulated form of active cell death
defined by characteristic biochemical and morphological
criteria. A large number of anti-cancer agents with widely
differing modes of action have been demonstrated to
induce apoptosis in vitro, suggesting this as a significant
final common pathway for exerting their clinical effects.
Mechanisms that suppress apoptosis may be important in
the development of intrinsic and acquired resistance to
cytotoxic drugs [3].
It was suggested more than 20 years ago that apoptosis
might account for much of the spontaneous cell loss
(known from kinetic studies) to occur in many tumors
and its extent often is enhanced by well-established
modalities such as chemotherapy, irradiation and hor-
mone ablation. However, during the past few years,
advances in the understanding of the control of apoptosis
at the molecular level has extended its potential oncologic
significance far beyond the mere provision of a mechanis-
tic explanation for tumor cell deletion. In particular, the
discovery that the products of certain proto-oncogenes
can regulate apoptosis has opened up exciting avenues for
future research [4].
The protean effects of various neoplastic agents on synthe-
sis of DNA, RNA, and inhibition of synthesis which may
or may not lead to cell death, requires only that some crit-
ical concentrations of active drug or metabolite be present
in a cell. Proliferating normal cells may therefore be sub-
ject to the same detrimental effects of chemotherapy expe-
rienced by neoplastic tissue and successful chemotherapy
dictates that recuperative abilities of normal tissues are
greater than those of cancer. The two tissues generally
most adversely affected by antineoplastics are the hemo-
poetic cells of the bone marrow and the epithelium of the
aero digestive tract as a result of high growth fractions and
short cycling times of the cells. The ability of the cancer
patients to perform normal activities and function is also
recognized both as a determinant of how well the patient
may respond to chemotherapy and an index of the general
toxicities of the anti cancer agents.
A variety of anti-cancer drugs have been shown to induce
extensive apoptosis in rapidly proliferating "normal" cell
population and the tumors alike. Thus enhanced apopto-
sis is also likely to be responsible for many of the adverse
effects observed following chemotherapy [5]. Apoptosis
being the common final pathway both for tumoricidal
effect and also for the toxic side effects, a significant corre-
lation should therefore exist between the effects and the
toxicity produced. Toxic effects could thus serve as reliable
indicators of apoptosis
Apoptosis is a regulated phenomenon capable of being
inhibited and activated. Indeed there is evidence that
stimulation of some cells by trophic cytokines or increase
in their levels of expression of Bcl-2 proto-ontogeny can
greatly increase their resistance to the apoptosis-inducing
effects of anticancer drugs. Thus Bcl-2 proto-ontogeny
expression may be implicated in the development of
resistance of tumors to therapeutic agents and may con-
tribute to tumor growth and perhaps to ontogenesis by
allowing the inappropriate survival of cells with DNA
abnormalities [6].
Deregulated expression of the Bcl-2 protein represents the
best-known example of a potent blocker of apoptosis.
Over expression of Bcl-2 has now been shown to protect a
wide variety of cell types from induction of apoptosis by
many different anticancer agents. Several homologues of
Bcl-2 protein have also been shown to act as inhibitors of
apoptosis, including Bcl-Xl and others as apoptotic pro-
teins such as Bax. In vitro data suggest that it is the relative
ratios of anti-apoptotic and pro-apoptotic proteins that
determine the likelihood of cells to undergo apoptosis in
response to chemotherapeutic drugs [2,7]
The increasing use of pre-operative chemotherapy (PCT)
in breast cancer offers an in vivo test bed to further confirm
the clinical relevance of these observations. The clinical
response or the absence of response along with the toxicBMC Cancer 2004, 4:48 http://www.biomedcentral.com/1471-2407/4/48
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effects observed could well help predict the outcome with
a particular chemotherapeutic regime and facilitate plan-
ning of an alternate regime for better response [5-8].
It is vital to assess the response to NACT in order to tailor
the regime for a particular patient to predict the intrinsic
or acquired chemo resistance. DNA-damaging agents such
as chemotherapeutic drugs can induce apoptosis and
increased resistance to chemotherapeutic agents, which
has been found to be associated with decreased capacity to
undergo apoptosis [5-9]. Central to this are proteins that
modulate apoptosis, including bcl-2 and bax products.
The change in expression of apoptotic markers brought
about by various chemotherapeutic regimens is being
used to identify drug resistance in the tumor cells. Various
other biological markers like p-glycoprotein expression
have also been used to predict the response to neoadju-
vant chemotherapy [9-11].
The clinical response along with complete pathological
response (CPR) is still considered a surrogate marker of
response against which all other predictive markers are
compared. The need to have a reliable and inexpensive
predictor of response in a third world scenario can not be
over emphasized since majority of patients present rela-
tively late and the resources are limited and scarce [2,3].
Since both the response and drug related toxicity due to
chemotherapeutic agents are the result of the same com-
mon final pathway of apoptosis the toxicity due to chem-
otherapy along with clinical response may be utilized as a
cost-effective and reliable indicator (predictor) of
response to neo-adjuvant chemotherapy. Against this
background a prospective study was contemplated with
the following aims and objectives:
1. To assess the clinical and immunohistochemical
response to NACT in patients with LABC.
2. To correlate immuno-histochemical (apoptotic mark-
ers i.e. Bcl-2/Bax ratio) and clinical response to the drug
induced toxicity.
3. To ascertain whether the drug induced toxicity could be
utilized as a reliable indicator and predictor of response to
neoadjuvant chemotherapy.
Methods
50 FNAC proven cases of locally advanced breast carci-
noma according to AJCC (American Joint Committee On
Cancer) classification were included in the study
A thorough clinical and ultrasonographic examination
(USG) of all the patients including the opposite breast
was performed to stage the disease accurately. A core
biopsy using a tru-cut needle was performed for immuno-
histochemical estimation of the apoptotic markers i.e.
base-line Bcl-2/Bax ratio before initiating the chemother-
apy. Routine and metastatic work up was done including
complete blood examination (total blood count, platelet
count), chest radiograph, ECG (Echocardiography when
ECG had a positive finding), liver function tests, Bone
Scan, USG abdomen, KFT (Kidney function tests).
Patients were subjected to three cycles of FAC regime
(cyclophosphamide 600 mg/m2, adriamycin -50 mg/m2,
5-fluorouracil-600 mg/m2) at an interval of three weeks.
Before each cycle the patient was clinically and sonologi-
cally examined for the breast tumor size, axillary lymph
node status & appearance of systemic metastasis. All
patients were given the same antitoxicity treatment
according to a standardized unit protocol including ade-
quate hydration and inject able antiemetics before initiat-
ing the chemotherapy.
The patients were observed for three main toxicities of the
FAC regime i.e. vomiting, alopecia and leucopenia. Vom-
iting with minimum of four episodes on day one and two
after chemotherapy was taken as significant. Total alo-
pecia was considered significant. Leucopenia was assessed
in terms of the WHO grading of hematological toxicity.
All patients were subjected to Patey's modified radical
mastectomy three weeks after the last cycle and the speci-
men were again subjected to immuno-histochemistry to
evaluate for any change in the Bcl-2/Bax ratio and for the
histological tumor size, margins.
Objective clinical response was defined as >50% reduc-
tion in the tumor size after completion of three cycles of
NACT, as assessed clinically, sonologically and histologi-
cally. Immunohistochemical response was taken as
decrease in the Bcl-2/Bax ratio. Any increase or no change
in this ratio was considered as no response.
Immuno-histochemical methods
Biopsy specimen was preserved in buffered formalin solu-
tion. Five-micron sections were prepared from paraffin
embedded blocks on poly-l-lysine coated glass slides. Sec-
tions were deparaffinized in xylene for 15 min. and
hydrated in alcohol for 15 minutes. Further, incubation
was done in 0.3% hydrogen peroxide in methanol solu-
tion for 45 min. The slides were washed with citrate buffer
and kept in a water bath at 90–95°C for 45 min. for anti-
gen retrieval. Sections were washed with Tris buffer saline
(TBS) solution and incubated with blocking antibodies
(DAKO monoclonal mouse antihuman Bcl-2 oncopro-
tein for Bcl-2 expression and polyclonal rabbit antihuman
for Bax expression) at 37°C. Sections were washed with
TBS solution. Incubation with avidin-biotin complex
(ABC) was done at 37°C for one hour and washed withBMC Cancer 2004, 4:48 http://www.biomedcentral.com/1471-2407/4/48
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TBS solution. 3,3 Diaminobenzidine tetra hydrochloride
solution applied for 3–5 min. Counter-staining with
haemotoxylin solution done for 3–5 min. Sections were
washed with distilled water, air dried and mounted using
DPX mountant.
For Bax, positive controls were taken as germinal centers
of the lymphoid follicles and normal breast tissue and
negative control was taken as the test slide without pri-
mary antibody. For Bcl-2, positive controls were the man-
tle zone of lymphoid follicles and the negative controls
were the test slides without primary antibody.
The pattern of positive staining for bcl-2 and bax was cytoplas-
mic, granular.
The primary antibodies for bcl-2 and bax were procured from
DAKO.
Bax-Rabbit Anti-Human code no. A 3533.
Bcl-2 Monoclonal Mouse Anti-Human code no. M 0887.
Dilution for both was 1: 40.
The results were interpreted on the basis of two criteria:
(1) Percentage of cells showing immune bodies; <5%:
score = 0, 5–25%: score = 1, 25–75%: score = 2, >75%:
score = 3
(2) Intensity of staining; mild: score = 1, moderate: score
= 2, intense: score = 3.
"Since there was a strong correlation between the intensity of
staining and percentage of cells showing immune bodies, the
percentage of cells showing immune antibodies alone was con-
sidered for calculating the bcl-2/bax ratio".
Statistics
Descriptive studies were performed with SPSS version 10.
The significance of response assessed using paired t-test.
Significance of correlation between various variables
assessed using chi-square test and coefficient of correla-
tion was calculated by Pearson correlation coefficient.
Results
50 cases of locally advanced breast cancer were included
in this study. Mean age of the patients was 45.5 years
(range: 28 to 71 years) and 53.3% patients were pre-men-
opausal. Size of the tumor was measured clinically as well
as by ultrasound and the patients were subdivided into
four groups: <5 cm(0%), 5–8 cm(56.6%), 8–10
cm(26.6%), >10 cm(16.6%). According to the axillary
lymph node status the patients were divided into three
groups: N0 (0%), N1 (33%), N2 (67%).
Objective clinical response was defined as more than 50%
reduction in the tumor size after three cycles of neoadju-
vant chemotherapy. Immuno-histochemical response was
defined as decrease in the Bcl-2/Bax ratio.
Clinical response including the reduction in the tumor
size and axillary lymph node status was observed in 70%
of patients and was found to be statistically significant (p
< 0.0001). There were no patients in the No group and
29.4%of the N1 patients were down staged to N0
while70.6% remained N1. In patients with N2 disease
7.7% were down staged to N0 status while 46.2% were
downstaged to N1 status and 46.2% did not show any
response. Immuno-histochemical response was observed
in 60% and was also found to be statistically significant (p
= 0.008). Correlation between immuno-histochemical
and clinical response was also found to be statistically sig-
nificant (p < 0.0001) [Table 1].
Acute vomiting was observed in 63.3% patients. 81% clin-
ical responders had vomiting (p = 0.002) and 78% immu-
nohistochemical responders also had vomiting which was
statistically significant (p = 0.04). Alopecia was observed
in 86% clinical responders (p = 0.000) and 94% immuno-
histochemical responders (p = 0.000), which was also sig-
nificant. Leucopoenia was observed in only 14% and 17%
of clinical and immuno-histochemical responders respec-
tively and was found to be an insignificant predictor of
response in the present study. When multiple toxicities
were correlated with the clinical and immuno-histochem-
ical response, 46.7% of patients had both acute vomiting
and alopecia. 67% clinical responders (p = 0.001) had
both vomiting and alopecia.72% immunohistochemical
responders (p = 0.001) had both vomiting and alopecia.
A significant positive correlation was observed between
the presence of vomiting (r = +0.558), alopecia(r =
+0.802) and response to neoadjuvant chemotherapy. A
significant negative correlation was observed between the
absence of side effects and poor response to neoadjuvant
chemotherapy (Table 2).
Discussion
Carcinoma of the breast is the leading cause of cancer in
women all over the world and the second most common
malignancy in India after carcinoma of the uterine cervix
[1]. No other common epithelial cancer has been so care-
fully studied and so extensively characterized biologically
[1,2]. In developing countries like India rate of locally
advanced breast cancer at first diagnosis is estimated to be
as high as 25%–30%[2,5]. The treatment of locally
advanced breast carcinoma (LABC) has also evolved fromBMC Cancer 2004, 4:48 http://www.biomedcentral.com/1471-2407/4/48
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primarily local modalities to treatment regimens that
combine both systemic and local therapy. The realization
that patients with LABC are likely to have undetectable
micro metastases at diagnosis has lead to systemic treat-
ment assuming major focus of the multi-modality
approach as the studies have confirmed that surgery alone
is an inadequate treatment in the management of these
patients. Even aggressive surgical techniques have been
observed to have a higher incidence of local recurrence in
these patients [10,11]. Most importantly surgery does not
change the pattern of distant failure in patients who prob-
ably have micrometastatic disease at the time of diagnosis
[10-13]. Multi-modality therapy that included surgery,
radiation therapy, chemotherapy, hormonal therapy has
had the greatest impact on survival in patients with LABC
[10-13].
Neoadjuvant chemotherapy (NACT)
A new approach in the form of neoadjuvant chemother-
apy was first reported in the 1970s and was initially uti-
lized to convert unresectable tumors to smaller tumors
making them more amenable to local control with either
surgery or radiotherapy. An added advantage of this
approach was the ability to assess patient's response to
treatment both clinically after a defined number of
courses of chemotherapy and pathologically after surgical
resection. Perez and colleagues reported their results of a
pilot study by the South-Eastern Cancer Study Group in
1979 that the primary tumor showed partial regression
(>50%)in 65% of patients after two courses of FAC [16].
NACT has also shown benefits in the operable breast can-
cers by increasing the chances of breast conservation by up
to 90% in some trials [10-13]. The other important advan-
tage of NACT is that it represents an in vivo chemo sensi-
tivity test for assessment of tumor response from which
prognostic information can be obtained. It provides an
early treatment of the micrometastatic disease, counteract-
ing the increased growth rate possibly determined by the
shrinkage of the tumor. The down staging converts an
inoperable case amenable to curative resection [10-13].
Table 1: n = 50
Clinical response Clinical no 
response
Immuno-histochemical 
response
Immuno-histochemical no 
response
Mean age 45.5 years
Range 28–71 yrs
Menopausal status
Pre-menopausal 53.3% 62.5% 37.5% 56.2% 43.8%
Post-menopausal 46.7% 71.4% 28.6% 64.2% 35.8%
Tumor size
< 5  c m 0 % --- -
5–8 cm 56.6% 68.7% 31.3% 60% 40%
8–10 cm 26.6% 75% 25% 60% 40%
>10 cm 16.6% 66.6% 33.3% 60% 40%
Axillary lymph nodes
N 0 0 % --- -
N1 33% 29.4%(toN0) 70.6% 60% 40%
N2 67% 7.7%(N0), 
46.2%(N1)
46.2% 60% 40%
Total 70% (p < 0.0001) 30% 60%(p = 0.008) 40%
Table 2: n = 50
Total N = 50 Clinical responders 
N = 35
Clinical non-responders 
N = 15
Immuno-histochemical 
responders N = 30
Immuno-histochemical 
non-responders N = 20
Acute vomiting 63.3% 81%(p = 0.002) 22.2% 78%(p = 0.04) 41.7%
Alopecia 60% 86%(p = 0.000) 0% 94%(p = 0.000) 8.3%
Leucopenia 10% 14%(NS) 0% 17%(NS) 0%
Alopecia+Acute 
vomiting
46.7% 67%(p = 0.001) 0% 72%(p = 0.001) 8.3%BMC Cancer 2004, 4:48 http://www.biomedcentral.com/1471-2407/4/48
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Apoptosis
Introduced by Kerr et al (1972) to describe characteristic
morphological changes seen during programmed cell
death [3]. It is defined as a closely regulated form of active
cell death defined by characteristic biochemical and mor-
phological criteria [3,14,15]. A wide range of anticancer
drugs with widely differing modes of action have been
demonstrated to induce apoptosis in vitro, suggesting this
as a significant common final pathway through which
they exert their clinical effect. Further more the mecha-
nisms that suppress apoptosis may be important in the
development of acquired resistance to cytotoxic drugs.
Apoptosis or programmed cell death plays an important
role in the regulation of tissue development, differentia-
tion and homeostasis. It is therefore possible that deregu-
lation of apoptosis contributes to the pathogenesis of
cancer [3,13-15]. Apoptosis can be differentiated bio-
chemically and morphologically from necrosis by the fol-
lowing criteria [16]:
(1) Chromophin condensation
(2) Membrane blebbing
(3) Appearance of apoptotic bodies
(4) Fragmentation of genomic DNA
Certain biochemical and genetic events have been identi-
fied that are associated with multiple cell types including
mammary epithelium. These include the DNA fragmenta-
tion via end nuclease activation and cleavage of intracel-
lular proteins, expression of bcl-2 family members, tumor
suppressor gene p-53 directed events, proto-oncogene
activation and activation of transmembrane receptor sign-
aling pathways such as tumour necrosis factor [4,17-22].
Although little is known about the mechanisms, which
regulate apoptosis in epithelial cells, it is conceivable that
defects in apoptosis related genes are involved in the
pathogenesis of human cancers. The hypothesis is sup-
ported by the fact that the tumor suppressor gene product
p-53, which is frequently mutated or deleted in breast can-
cer, is involved in regulating apoptosis [23].
The heterogeneous nature of breast cancer has resulted in
overwhelming interest in search for prognostic markers to
identify patients who might benefit most from the thera-
peutic modalities available.
Assessment of apoptosis and individual components of
apoptotic pathway are therefore relevant in determining
prognosis in a particular patient [24]. DNA damaging
agents such as ionizing radiations and chemotherapeutic
drugs also induce apoptosis. Sakakura et al have shown an
association between increased resistance to chemothera-
peutic agents and decreased capacity to undergo apoptosis
[25]. Central to this response are proteins that modulate
apoptosis, including bcl-2 and bax gene products.
Bcl-2 is anti-apoptotic in function, whereas bax is proap-
optotic and it is the interaction between the two that
determines the likelihood of a tumor to undergo cytotoxic
drug mediated regression. Therefore any increase in bcl-2
or decrease in bax will push the balance towards chemo
resistance and an increase in bax or decrease in bcl-2 will
result in increased apoptosis [26-30].
It was observed in a study conducted by Kymionis et al
[15] that increase in the ratio of anti apoptotic protein bcl-
2 to pro-apoptotic protein i.e. bax results in markedly
enhanced resistance of tumor cell lines to the cytotoxic
effects of essentially all currently available chemothera-
peutic drugs.
In the present study the clinical response in terms of
reduction of tumor size and immuno-histochemical
response in terms of change of bcl-2/bax ratio correlated
significantly with the drug induced toxicity following
NACT.
Toxicity related to chemotherapeutic agents [19-23]
The time course of various toxic manipulations depends
on the drug, its dose and frequency of administration,
intrinsic characteristics of the tissue of interest and any
local circumstances (e.g. radiation therapy, infection,
trauma). There are few general rules however like mucosal
toxicities of pain, erythema, ulceration etc. occur 3–10
days after the administration of most offending drugs.
Bone marrow effects can be manifestated a few days later
averaging 7–14 days. The recovery of normal functioning
tissues in both cases is well under way 4–5 days after the
zenith of the toxic effects.
Alopecia may involve the scalp or the whole body can
present within 2 weeks of the drug dose or be a progressive
cumulative event. Other cumulative toxicities seen only
after administration of a certain quantity of drug over
some length of time include cardiomyopathy from
anthracyclins.
Cyclophosphamide
An alkylating agent belonging to the nitrogen mustard
subgroup. It is inactive as such produces few acute effects
and is not locally damaging. It is transformed in to active
metabolites like aldophosphamide and phospharimide
mustard in the liver, which then produces the wide variety
of antitumour action. The prominent side effects are alo-
pecia and cystitis, which are caused by another metabolite
acrolein.BMC Cancer 2004, 4:48 http://www.biomedcentral.com/1471-2407/4/48
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5-Fluorouracil
It is a pyrimidine antagonist and is converted in the body
to the corresponding nucleotide, 5-fluro-2-deoxy-uridine
monophosphate, which inhibits thymidine synthetase
and blocks the conversion of deoxyuridilic acid to deox-
ythymidilic acid. Selective failure of DNA synthesis occurs
due to non-availability of thymidylate. Flourouracil may
itself get incorporated in to nucleic acids and this may
contribute to its toxicity. Even resting cells are affected,
though multiplying cells are more susceptible like the
cells in the gastrointestinal tract (GIT) and bone marrow.
Doxorubicin
It is an anti tumor antibiotic and is capable of causing
breaks in the DNA strands by activating topoisomerase II
and generating quinone type free radicals. They have
mutagenic potential. Maximum action is exerted at S
phase, but toxicity is usually exerted in G2 phase. Cardio-
toxicity is a unique side effect. Rapidly multiplying cells
Immuno-histochemistry showing positive (moderate) staining  of the tumor cells for Bax antibody Figure 1
Immuno-histochemistry showing positive (moderate) staining 
of the tumor cells for Bax antibody.
Immuno-histochemistry showing positive (intense) staining of  the tumor cells for Bax antibody Figure 2
Immuno-histochemistry showing positive (intense) staining of 
the tumor cells for Bax antibody.
Immunohistochemistry showing positive (moderate) cyto- plasmic staining of the tumor cells for the Bcl-2 antibody Figure 3
Immunohistochemistry showing positive (moderate) cyto-
plasmic staining of the tumor cells for the Bcl-2 antibody.
Immuno-histochemistry showing positive (intense) cytoplas- mic staining of the tumor cells for Bcl-2 antibody Figure 4
Immuno-histochemistry showing positive (intense) cytoplas-
mic staining of the tumor cells for Bcl-2 antibody.BMC Cancer 2004, 4:48 http://www.biomedcentral.com/1471-2407/4/48
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are more susceptible therefore it also acts on cells of GIT,
bone marrow in addition to the tumor cells.
Leucopenia has not been observed to be a frequently
encountered chemotherapy induced toxicity using com-
monly used regimen in most of the studies [19-24]. This
was observed in the present study also.
Conclusions
The rapidly proliferating normal and tumor cells are more
susceptible to the action of chemotherapeutic agents,
which could explain the significant correlation observed
between the effects and the toxicity in the present study.
There was a strong correlation observed between the
immunohistochemical response (bcl-2/bax ratio), clinical
response and drug toxicity. This indirectly indicates a cor-
relation between chemotherapy induced apoptosis and
the toxicity and therefore like apoptotic markers, chemo-
therapy induced toxic effects along with objective clinical
response could serve as reliable and cost-effective indica-
tors or predictors of response to NACT in patients with
LABC. While many biological markers are in use and
many are under trial to tailor the chemotherapy for a par-
ticular patient, most of these markers including apoptotic
markers or p-glycoprotein etc. are not very frequently
available and are expensive for a third world cancer set up.
Thus the chemotherapy-induced toxicity along with clini-
cal response may be utilized as a cost effective and reliable
predictor of response to NACT in patients with LABC. This
would also serve as an intermediate end point in deter-
mining drug sensitivity for adjuvant treatment, especially
when adjuvant therapy is planned with the same regimen
as induction chemotherapy. This can also help in plan-
ning an alternative regime in non-responders.
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